Taiwan Liposome Statistics
Share Statistics
Taiwan Liposome has -
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -5 and the forward
PE ratio is null.
Taiwan Liposome's PEG ratio is
-4.93.
| PE Ratio | -5 |
| Forward PE | n/a |
| PS Ratio | 48.21 |
| Forward PS | n/a |
| PB Ratio | 11.22 |
| P/FCF Ratio | -5.4 |
| PEG Ratio | -4.93 |
Financial Ratio HistoryEnterprise Valuation
Taiwan Liposome has an Enterprise Value (EV) of 4.24B.
| EV / Sales | 41.58 |
| EV / EBITDA | -4.66 |
| EV / EBIT | -4.84 |
| EV / FCF | -4.66 |
Financial Position
The company has a current ratio of 4.11,
with a Debt / Equity ratio of 1.52.
| Current Ratio | 4.11 |
| Quick Ratio | 4.11 |
| Debt / Equity | 1.52 |
| Debt / EBITDA | -0.73 |
| Debt / FCF | -0.73 |
| Interest Coverage | -60.12 |
Financial Efficiency
Return on Equity is -224.54% and Return on Invested Capital is -89.05%.
| Return on Equity | -224.54% |
| Return on Assets | -56.21% |
| Return on Invested Capital | -89.05% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | undefined |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1.13M |
| Effective Tax Rate | -0.12% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is 0.8, so Taiwan Liposome's
price volatility has been higher than the market average.
| Beta | 0.8 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 17,612 |
Income Statement
In the last 12 months, Taiwan Liposome had revenue of 101.93M
and earned -983.31M
in profits. Earnings per share was -24.89.
| Revenue | 101.93M |
| Gross Profit | 101.93M |
| Operating Income | -983.11M |
| Net Income | -983.31M |
| EBITDA | -909.66M |
| EBIT | -965.82M |
| Earnings Per Share (EPS) | -24.89 |
Full Income StatementBalance Sheet
The company has 1.34B in cash and 667.38M in
debt, giving a net cash position of 675.28M.
| Cash & Cash Equivalents | 1.34B |
| Total Debt | 667.38M |
| Net Cash | 675.28M |
| Retained Earnings | -2.7B |
| Total Assets | n/a |
| Working Capital | n/a |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -875.19M
and capital expenditures -34.38M, giving a free cash flow of -909.57M.
| Operating Cash Flow | -875.19M |
| Capital Expenditures | -34.38M |
| Free Cash Flow | -909.57M |
| FCF Per Share | -23.02 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -964.51% and -964.71%.
| Gross Margin | 100% |
| Operating Margin | -964.51% |
| Pretax Margin | -963.6% |
| Profit Margin | -964.71% |
| EBITDA Margin | -892.45% |
| EBIT Margin | -964.51% |
| FCF Margin | -892.36% |
